Anticardiolipin Antibodies in Patients with Type 2 Diabetes Mellitus

Calvo-Romero, José Marı́a; Lima-Rodríguez, Esther María

doi:10.3121/cmr.2008.828

Cited by 5 publications

(4 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While there is an association between T1DM and anticardiolipin antibodies, this has not been the case for T2DM. 94 Further studies will need to determine if patients with DMI have a high prevalence of anticardiolipin antibodies.…”

Section: Pathophysiologymentioning

confidence: 99%

Diabetic muscle infarction: a systematic review

Horton

Taylor

Ragland

et al. 2015

BMJ Open Diab Res Care

198

View full text Add to dashboard Cite

ContextDiabetic muscle infarction (DMI) is a rare complication associated with poorly controlled diabetes mellitus. Less than 200 cases have been reported in the literature since it was first described over 45 years ago. There is no clear ‘standard of care’ for managing these patients.Evidence acquisitionPubMed searches were conducted for ‘diabetic muscle infarction’ and ‘diabetic myonecrosis’ from database inception through July 2014. All articles identified by these searches were reviewed in detail if the article text was available in English.Evidence synthesisThe current literature exists as case reports or small case series, with no prospective or higher-order treatment studies available. Thus, an evidence-based approach to data synthesis was difficult. The available literature is presented objectively with an attempt to describe clinically relevant trends and findings in the diagnosis and management of DMI.ConclusionsEarly recognition of DMI is key, so appropriate treatment can be initiated. MRI is the radiological study of choice. A combination of bed rest, glycemic control, and non-steroidal anti-inflammatory drug therapy appears to yield the shortest time to symptom resolution and the lowest risk of recurrence.

show abstract

Section: Pathophysiologymentioning

confidence: 99%

Diabetic muscle infarction: a systematic review

Horton

Taylor

Ragland

et al. 2015

BMJ Open Diab Res Care

198

View full text Add to dashboard Cite

show abstract

“…Several studies have attempted to explore the relationship between these two conditions primarily by investigating the prevalence of aPL in populations of diabetic patients, both insulin dependent and independent. [65][66][67][68][69][70][71][72][73][74][75][76][77][78][79][80][81] Although some studies reported higher aPL titers in association with diabetes, other studies failed to replicate this data. Moreover, some researchers have linked the presence of aPL in the sera of diabetic patients to macrovascular diabetic complications.…”

Section: Diabetes Mellitusmentioning

confidence: 99%

Antiphospholipid Syndrome: Endocrinologic Manifestations and Organ Involvement

Mehdi

Salti

Uthman

2011

Semin Thromb Hemost

View full text Add to dashboard Cite

Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by thrombotic tendency that affects most organ systems in the human body. In this report, we present a review of the endocrinologic manifestations associated with APS by evaluating the medical literature from 1968 to 2009 using MEDLINE and these keywords: APS, antiphospholipid syndrome, antiphospholipid antibodies, anticardiolipin antibodies, lupus anticoagulant, anti β-2 glycoprotein I, pituitary, adrenal, thyroid, parathyroid, ovary, testes, diabetes mellitus, and diabetes insipidus. Adrenal insufficiency was found to be the most common endocrine manifestation associated with APS. Autoimmune thyroid disease was associated with increased titers of antiphospholipid antibodies (aPL) without any APS clinical manifestations. In addition, hypopituitarism and Sheehan syndrome are increasingly being reported in association with aPL. Data regarding the prevalence and significance of aPL in diabetic patients remains uncertain. Finally, only a few cases of ovarian and testicular derangements have been reported. APS should be considered in any patient with adrenal insufficiency even in the absence of other thrombotic manifestations. It is also advisable to assess aPL in the sera of patients presenting with pituitary insufficiency. Further studies are needed to clarify the relationship between aPL and thyroid disorders and diabetes mellitus.

show abstract

“…[20] According to the study of Galtier-Dereure et al, [21] uncomplicated diabetes was not associated with APL antibodies; whereas phospholipid-binding antibodies correlated with macroangiopathy or nephropathy. Palomo et al [22] and Calvo-Romero et al [3] observed that these antibodies in diabetic pa-tients were not correlated with vasccular complications. Mohammed et al [23] reported higher anticardiolipin IgG and IgM antibodies in type 1 diabetic children, especially recent-onset diabetes, compared to healthy controls.…”

Section: Discussionmentioning

confidence: 97%

“…Previous data reflect controversy about the prevalance of these antibodies in diabetes mellitus and the possible implications. [3] It has been suggested that antiphospholipid antibodies directed against endothelial antigens could be responsible for vascular injury. There is a pathological shift from an antithrombotic to a thrombotic state even in the early phases of diabetes.…”

Section: Introductionmentioning

confidence: 99%

Comparison of serum anticardiolipin antibodies and carotid intima media thickness in diabetic patients

Kar¹,

Erdenen²,

Altunoğlu³

et al. 2011

Istanbul Tip Derg

View full text Add to dashboard Cite

Diyabetik hastalarda fibrinolitik aktivitede azalma ve trombosit aktivitesinde değişiklikler olur ve bunlar prokoagülan bir durum yaratır. Hiperglisemi varlığında degrade endotelden kaynaklanan antikardiyolipin antikorların (ACA) fosfolipidler üzerine etkisi ve bu antikorlarla diyabetin mikro ve makrovasküler komplikasyonlarının ilişkileri araştırılmıştır. Çalışmamızda tip 1 ve tip 2 diyabetik hastalarda serum ACA düzeyleriyle karotis intima media kalınlığının (CIMT) ilişkisi incelenmiştir. Gereç ve Yöntem: Hastalar iki gruba ayrıldı: Grup I: Tip I diyabetes mellitus (DM) (n=15) ve Grup II: Tip II DM (n=45). Serum ACA IgG düzeyleri ELISA yöntemiyle (Trinity Biotech, USA) ölçüldü. İstatistiksel analiz için Mann-Whitney U testi kullanıldı. Bulgular: Gruplar diyabetin süresi açısından benzerdi (p=0,261). İki grup arasında ACA düzeyleri bakımından fark yoktu. Spot idrarda mikroalbümin seviyeleri ve CIMT grup II'de istatistiksel olarak belirgin yüksekti (sırasıyla p=0,0001, p=0,001). ACA ile CIMT arasında korelasyon bulunmadı (p=0,258). Sonuç: İkinci gruptaki hastalar daha yaşlı olup hipertansiyon ve metabolik sendromları olduğundan, beklendiği gibi endotel disfonksiyonundan dolayı mikroalbüminuri ve CIMT değerleri bu grupta daha yüksekti. DM hastalarında ACA ve CIMT ilişkisi konusunda delil sağlamak için büyük popülasyonlu çalışmalar gereklidir. Anahtar sözcükler: Antikardiolipin antikorları; diabetes mellitus; karotis intima media kalınlığı.

show abstract

Anticardiolipin Antibodies in Patients with Type 2 Diabetes Mellitus

Cited by 5 publications

References 8 publications

Diabetic muscle infarction: a systematic review

Diabetic muscle infarction: a systematic review

Antiphospholipid Syndrome: Endocrinologic Manifestations and Organ Involvement

Comparison of serum anticardiolipin antibodies and carotid intima media thickness in diabetic patients

Contact Info

Product

Resources

About